PDCD1 and metastatic melanoma: As a validation cohort (16), 101 metastatic melanoma patients treated with anti-PD-1 agent (Nivolumab) were examined to verify the favorable response to anti-PD-1 immunotherapy in the high-Tfh infiltration group.